エピソード

  • REGN Today - Aug 12: Stock Slightly Down

    REGN Today - Aug 12: Stock Slightly Down
    2026/08/12
    Hey there! It’s Joey here, your friendly longtime investor, and today we're talking about Regeneron Pharmaceuticals, or REGN for short. It was a red day for them, down just a tiny bit—like, 0.31%.

    So, what went down? The stock barely moved, but it did get a little smoked compared to some of its competitors. You know how it is—some days you’re just not in the spotlight, and today was one of those days for Regeneron. There was a bit of chatter about their valuation after some recent earnings reports, but honestly, nothing too wild happened to shake things up.

    Now, why the dip? Well, a few articles pointed out that Regeneron’s performance wasn’t exactly stellar compared to other stocks in the same space. People were looking at their competitors and thinking, “Wow, they’re doing better.” Plus, there was some buzz about investment firms adjusting their positions. Like, Handelsbanken trimmed their stake, and that kind of stuff can make folks a little jittery. It’s like when your friend suddenly decides they don’t want to hang out anymore—kinda makes you question things, right?

    On the horizon, it’s worth knowing that Regeneron has been on a roll recently, soaring about 21.9% in the month leading up to today. So, while today was a bit of a slow bleed, they’ve had their moments.

    Alright, that’s the scoop for today! Just remember, this is all for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • REGN Today - Aug 11: Slight Dip Amid Mixed News

    REGN Today - Aug 11: Slight Dip Amid Mixed News
    2026/08/11
    Hey there! It’s Joey here, your friendly investor buddy. Let’s chat about Regeneron Pharmaceuticals, ticker REGN. Today was a bit of a red day, with the stock dipping just a smidge, down about a quarter percent.

    So, what went down? Well, today’s trading was pretty chill overall. REGN barely moved, just a slight drop, but it seems like the stock was holding its own against some of its competition. There was some strong trading action in the biotech space, but our buddy Regeneron just kinda floated along.

    Now, let’s get into the why behind this move. NewEdge Advisors just announced they’re holding about $5.88 million in REGN. That’s some solid backing, right? Plus, Contravisory Investment Management scooped up over 10,000 shares. Always nice to see folks betting on the stock. On the flip side, there was news about a class action deadline coming up that might’ve put a little weight on the stock. It’s like when you’re cruising along, and then a random speed bump shows up outta nowhere – yeah, that one stung a bit.

    And here’s something to keep in mind: analysts are still giving REGN a “moderate buy” rating, which is kinda reassuring. It means people still believe in the potential here, even if today felt a little sleepy.

    So, to wrap it up, REGN had a quiet day, dipped just a tad, but there’s still some interest from investors, and analysts are mostly positive. Just remember, this is all for fun and info, not financial advice. Catch you later, and happy investing!
    続きを読む 一部表示
    1 分
  • REGN Today - Aug 10: Mixed News on Buybacks and Dividends

    REGN Today - Aug 10: Mixed News on Buybacks and Dividends
    2026/08/10
    Hey there! It’s Joey here, your friendly neighborhood investor, and today we’re chatting about Regeneron Pharmaceuticals, also known as REGN. So, how’d it do today? It was a green day, up about 1.5%. Not too shabby!

    Now, let’s break down what went down. The stock had a pretty solid day, bouncing up a bit, but it wasn’t all sunshine and rainbows. There was some action with shares changing hands—some folks buying and selling like it was a game of hot potato. Contravisory Investment Management picked up over 10,000 shares, which is a good sign. But then, on the flip side, Beacon Investment Advisory sold off about 9,000 shares. So, it’s like a mixed bag of vibes today.

    But why the movement? Well, it seems like there’s a lot of chatter about Regeneron’s buyback strategy and dividends. They’re keeping those in focus, and investors are paying attention. When a company talks about returning value to shareholders, it can make people feel a little more secure. Plus, there’s some buzz around their drug Dupilumab, which is showing promise for treating allergic fungal rhinosinusitis. That’s definitely a win for the company and could be driving some interest.

    One thing to keep an eye on? Regeneron’s fair value seems to be in sight, which could mean there’s more room for growth. It’s always good to know where a company stands in the market.

    So, to wrap this up, Regeneron had a decent day, with mixed news on buying and selling shares. They’re focused on buybacks and dividends, and their drug developments are looking promising. Just remember, this is all for your info and fun, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • REGN Today - Aug 09: Combo Drug Falls Short

    REGN Today - Aug 09: Combo Drug Falls Short
    2026/08/09
    Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Regeneron Pharmaceuticals today. So, REGN had a bit of a green day, up about one and a half percent. Not too shabby!

    Now, here’s the scoop. Regeneron’s stock had a pretty solid day overall, but there’s some drama behind the scenes. The big news? Their combo drug didn’t quite stack up against Merck’s Keytruda in a melanoma trial. Yeah, that one stung a bit, especially since investors had their hopes up for that one. When news like that drops, people tend to hit the sell button fast, but surprisingly, the stock held its ground pretty well.

    On the flip side, there’s some positive buzz around Regeneron keeping their buybacks and dividends in focus. It looks like they’re staying committed to returning value to shareholders, which is always nice to see. But that melanoma trial overshadowed a lot of the good vibes today.

    In terms of buying and selling, there were some interesting moves too. Beacon Investment Advisory sold a chunk of shares, while PensionDanmark decided to scoop up a few more. It’s like a little dance of buying and selling going on.

    One thing to keep an eye on is how they’re planning to navigate the fallout from that trial. They’re still in the game with other drugs and treatments, but that setback might make investors a bit jittery for a while.

    So, to wrap it up, Regeneron had a mixed bag today. A little bump up in price, but some serious news that could shake things up. Just remember, this is all for your info and entertainment. Always do your own homework before making any moves. Catch you later!
    続きを読む 一部表示
    1 分
  • REGN Today - Aug 08: Pension Fund Buys Shares

    REGN Today - Aug 08: Pension Fund Buys Shares
    2026/08/08
    Hey, what’s up! It’s Joey here, your friendly neighborhood investor. Let’s talk about Regeneron Pharmaceuticals, or REGN for short. Today was a pretty chill day for them, up about 1.6%. Not a crazy jump, but hey, green is green!

    So, here’s the scoop. REGN had a solid day, climbing a little thanks to some fresh buying action. PensionDanmark just snagged over 3,600 shares of Regeneron. That’s a nice little vote of confidence from a pension fund, right? When big players like that step in, it usually gets people talking and can give the stock a little boost.

    Now, why did we see this move today? Well, it seems like the market is still digesting some recent earnings news. There’s been chatter about Regeneron's revenues taking a hit, especially after some other biotech stocks have been in the spotlight for not-so-great reasons. But today wasn’t about that; it was about some folks stepping up to the plate and adding to their positions. So, while the market’s been a bit shaky, this pension fund’s move brought some positive vibes.

    One thing to keep in mind is that Regeneron has a notice coming up on September 14. Not sure what that’s about yet, but it could be something worth keeping an eye on. Could be good, could be not so good—who knows!

    Alright, to wrap it all up, Regeneron had a decent day, thanks to that big purchase. It’s always interesting to see how these big players can shake things up a bit. Remember, this is just for your info and a little entertainment. I’m just sharing what’s happening, not telling you what to do with your cash. Catch you later!
    続きを読む 一部表示
    1 分
  • REGN Today - Aug 07: New Investments and Class Action

    REGN Today - Aug 07: New Investments and Class Action
    2026/08/07
    Hey there! It’s Joey, your friendly stock enthusiast, here to break down today’s moves. Today, we’re talking about Regeneron Pharmaceuticals, and it was a bit of a mixed bag. The stock was up just a smidge, barely moving at 0.51%.

    So, what went down? Well, the trading volume was pretty steady, which is kinda normal for REGN. A couple of investment firms made some headlines today. Assenagon Asset Management scooped up over 37,000 shares, which is a nice little vote of confidence. And Segall Bryant & Hamill also jumped in with a fresh investment of a million bucks. Always nice to see folks putting their money where their mouth is, right?

    But here’s the kicker. There’s some chatter about a class action lawsuit for investors who lost money on REGN. Yeah, that one stung for a lot of people. It’s always a bit of a red flag when lawsuits start popping up, and I’m sure it’s got people talking.

    Now, why did the stock barely budge despite some positive vibes from those investments? Honestly, nobody really knows. Sometimes the market just decides to be chill, even when there’s a mix of good and bad news floating around.

    On the horizon, Barclays is sticking with their buy rating on Regeneron, which could give some folks a little boost of confidence. Ratings can play a big role in how investors feel, so that’s worth keeping an eye on.

    Alright, that’s the scoop for today! Just remember, I’m here to share info and keep it fun, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • REGN Today - Aug 06: Profit Slip Amid Trials

    REGN Today - Aug 06: Profit Slip Amid Trials
    2026/08/06
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about Regeneron Pharmaceuticals, or REGN, which had a bit of a rough day. It dropped just under half a percent—yeah, that one stung.

    So, what went down? REGN started off kinda steady but ended up getting smoked a bit. It closed down after some mixed news about their earnings and clinical trials. You know how it goes—people get jittery, and when that happens, they hit the sell button fast.

    Now, why did this happen? Well, there’s a lot swirling around Regeneron. First off, their earnings estimates are looking pretty good, hinting at some potential upside. But then you’ve got this nagging issue with their clinical trials, which reportedly led to a 9% drop earlier. Plus, there’s chatter about whether they’re prioritizing shareholder returns over the quality of earnings since profits seem to be slipping despite rising sales. It’s like a roller coaster over there—up one minute, down the next.

    On top of that, Segall Bryant & Hamill just made a new investment in Regeneron, dropping over a million bucks into the company. That’s a pretty big vote of confidence, but it didn’t seem to lift the stock today. And Barclays is still keeping their buy rating on REGN, which is nice, but again, the market didn’t react positively.

    One quick thing worth knowing: there’s a class action lawsuit related to securities fraud hanging over the company, and that’s probably adding to the nervous vibes among investors.

    So, that’s the scoop on Regeneron today. It’s a bit of a mixed bag right now, but that’s how the stock game goes. Remember, this is just for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • REGN Today - Aug 05: Clinical Trials Cause Concern

    REGN Today - Aug 05: Clinical Trials Cause Concern
    2026/08/05
    Hey there! It’s Joey, your friendly longtime investor, and I’m here to break down what happened with Regeneron Pharmaceuticals today. So, REGN had a bit of a mixed bag day, closing up about 1.75%. Not too shabby, but still a bit of a rollercoaster.

    So, what went down? Well, shares were sold off by MassMutual Private Wealth & Trust. That always raises some eyebrows, ya know? Plus, there’s been chatter about Regeneron’s clinical trials. Apparently, some results didn’t live up to the hype, which caused a bit of a stir. I mean, when clinical trials go sideways, it can make investors super nervous. And guess what? There’s even a class action lawsuit brewing. Yeah, that one stung.

    Now, let’s talk about why all this is happening. Regeneron has been trying to balance shareholder returns with the quality of their earnings. But with profits slipping even as sales are rising, folks are starting to question if they’re focused on the right things. It’s like, are they chasing quick gains instead of building something solid long-term? That uncertainty is never a good look for a stock.

    Oh, and here’s something to keep in mind. There’s a lot of buzz about other biotech stocks that could have some serious upside this month. So, while REGN has its challenges, the market's always shifting and there are opportunities popping up everywhere.

    Alright, that’s the scoop on Regeneron today! Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分